Daniel Matthew Wettstein

US Patent:

7202329, Apr 10, 2007

Filed:

Oct 4, 2001

Appl. No.:

09/972035

Inventors:

Daniel Albert Wettstein - Salt Lake City UT, US
Scott Morham - Salt Lake City UT, US
Kenton Zavitz - Salt Lake City UT, US

Assignee:

Myriad Genetics, Inc. - Salt Lake City UT

International Classification:

C07K 14/00

US Classification:

530300, 530350, 435 691, 4353201, 536 234, 536 2372

Abstract:

Isolated protein complexes are provided comprising Tsg101 and HIV GAGp6. The protein complexes are useful in screening assays for selecting compounds effective in modulating the Tsg101-HIV GAGp6 interaction within the protein complexes.

US Patent:

7297515, Nov 20, 2007

Filed:

Oct 28, 2002

Appl. No.:

10/282617

Inventors:

Philippe Szankasi - Salt Lake City UT, US
Kimberly Mauck - Sandy UT, US
Daniel Albert Wettstein - Salt Lake City UT, US

Assignee:

Myriad Genetics, Inc. - Salt Lake City UT

International Classification:

C12P 21/02
C12N 15/00
C12N 5/10
C12M 3/00
C07H 21/04

US Classification:

435 691, 435 701, 4353201, 4352523, 435325, 4352872, 536 235, 536 231

Abstract:

Novel zinc finger proteins and nucleic acids encoding the proteins are provided. The zinc finger proteins interact with ZNF202, a zinc finger protein that regulates the expression of a variety of genes involved in lipid metabolism and transportation. Modulation of the novel zinc finger proteins and their interactions with ZNF202 can be useful in the treatment of coronary heart diseases, dyslipidemia, dyscholesterolemia and obesity.

US Patent:

7335468, Feb 26, 2008

Filed:

Sep 15, 2003

Appl. No.:

10/663407

Inventors:

Kenton Zavitz - Salt Lake City UT, US
Scott Morham - Salt Lake City UT, US
Daniel Albert Wettstein - Salt Lake City UT, US

Assignee:

Myriad Genetics, Inc. - Salt Lake City UT

International Classification:

C12Q 1/70
A61K 39/21

US Classification:

435 5, 4242081

Abstract:

Isolated protein complexes are provided comprising Tsg101 and HIV GAG or GAGp6. The protein complexes are useful in screening assays for selecting compounds effective in modulating the Tsg101-HIV GAG or GAGp6 interaction within the protein complexes.

US Patent:

7595401, Sep 29, 2009

Filed:

May 14, 2007

Appl. No.:

11/748362

Inventors:

Ashok C. Bajji - Salt Lake City UT, US
Se-Ho Kim - Salt Lake City UT, US
Benjamin Markovitz - Salt Lake City UT, US
Richard Trovato - Salt Lake City UT, US
Rajendra Tangallapally - Salt Lake City UT, US
Mark B. Anderson - Salt Lake City UT, US
Daniel Wettstein - Salt Lake City UT, US
Mark Shenderovich - Murray UT, US
John A. Vanecko - Groton CT, US

Assignee:

Myriad Pharmaceuticals, Inc. - Salt Lake City UT

International Classification:

C07D 473/34
A61K 31/52
A61P 35/00

US Classification:

544276, 544118, 544277, 544265, 546226

Abstract:

The invention relates to compounds of Formula I.

US Patent:

8476285, Jul 2, 2013

Filed:

Jun 30, 2009

Appl. No.:

12/494917

Inventors:

Ashok C. Bajji - Salt Lake City UT, US
Se-Ho Kim - Salt Lake City UT, US
Benjamin Markovitz - Columbus OH, US
Richard Trovato - Salt Lake City UT, US
Rajendra Tangallapally - Salt Lake City UT, US
Mark B. Anderson - Salt Lake City UT, US
Daniel Wettstein - Salt Lake City UT, US
Mark Shenderovich - Salt Lake City UT, US
John A. Vanecko - Thousand Oaks CA, US

Assignee:

Myrexis, Inc. - Salt Lake City UT

International Classification:

A61K 31/52
C07D 473/34
A61P 35/00

US Classification:

51426322, 51426324, 51426321, 51426337, 51426338, 5142342, 51425216

Abstract:

The invention relates to compounds of Formulae I-III:.

US Patent:

20020173026, Nov 21, 2002

Filed:

Mar 14, 2002

Appl. No.:

10/099924

Inventors:

Daniel Wettstein - Salt Lake City UT, US
Daniel Cimbora - Salt Lake City UT, US

Assignee:

Myriad Genetics, Incorporated - Salt Lake City UT

International Classification:

C12N009/22
C12N009/64
C12P021/02
C12N005/06

US Classification:

435/199000, 435/226000, 435/069100, 435/320100, 435/325000

Abstract:

Protein complexes are provided comprising survivin and one or more proteins selected from the group consisting of HDLC1, beta-actin, DNA helicase II, COPP, OSTP, SLC8A1, A2-CAT. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with survivin and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

US Patent:

20020177152, Nov 28, 2002

Filed:

Mar 18, 2002

Appl. No.:

10/100503

Inventors:

Daniel Wettstein - Salt Lake City UT, US

Assignee:

Myriad Genetics, Incorporated - Salt Lake City UT

International Classification:

C12Q001/68
C12N009/02

US Classification:

435/006000, 435/069100, 435/189000, 435/320100, 435/325000

Abstract:

Protein complexes are provided comprising COX1 and one or more proteins selected from the group consisting of THR S14 and Opa1. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with COX1 and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

US Patent:

20030036163, Feb 20, 2003

Filed:

Jul 10, 2002

Appl. No.:

10/195142

Inventors:

Daniel Wettstein - Salt Lake City UT, US
Kimberly Mauck - Sandy UT, US

Assignee:

Myriad Genetics, Incorporated - Salt Lake City UT

International Classification:

C12P021/02
C12N005/06
C07K014/435
C07H021/04
C12N009/00

US Classification:

435/069100, 435/183000, 435/320100, 435/325000, 530/350000, 536/023200

Abstract:

Novel PN9826 protein and nucleic acids encoding PN9826 are provided. PN9826-containing protein complexes formed by PN9826 and a PN9826-interacting protein (e.g., LTBP1) are also provided. LTBP1 and PN9826 may be involved in common biological processes such as angiogenesis, metastasis, and cell growth and adhesion. Thus, the protein complexes as well as PN9826 can be used in screening assays to select modulators of PN9826 and the protein complexes formed by PN9826 and LTBP1. The identified modulators can be useful in modulating the functions and activities of PN9826 and protein complexes containing PN9826.